Pulling SEC filings + quote and writing the call…

Oaktree Specialty Lending Corp
Next earnings Aug 3, 2026 · consensus $0.36 EPS, $70.8M rev
Last earnings -5.7% on 2026-05-05
OCSL is a yield vehicle, not a P/E story — at 0.78x book with a 13% covered dividend, it's a hold for income but credit is softening.
Sources: SEC EDGAR (CIK 0001414932, latest 10-Q filed 2026-05-05) · EODHD · analysis by claude-code · as of 6/25/2026, 2:21:58 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Middling fundamentals and a rich price (~74% above fair value) leave little margin of safety — a wait-and-see.
OCSL is an Oaktree-managed BDC, so the headline 29.3x P/E on $0.39 diluted EPS is the wrong lens — BDCs are valued on NAV and dividend coverage, not GAAP earnings (which include unrealized mark-to-market on a $2.8B private-credit book). The right read: stockholders' equity of $1.47B on 88.1M shares implies NAV near $16.69, so $11.41 is roughly 0.78x book — a meaningful discount that already prices in credit stress, and one management explicitly flagged in MD&A ('our common stock has traded at prices below net asset value, and we may not be able to raise additional equity at prices below the then-current net asset value per share'). That discount is the floor under the thesis.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | $237M | $29.2M | $117M | $57.9M | $33.9M |
| Diluted EPS | $4.39 | $0.48 | $1.63 | $0.72 | $0.39 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Q2 FY26 10-Q filed; portfolio repositioning continues, leverage ~0.97x net
Q2 FY26 10-Q filed; portfolio repositioning continues, leverage ~0.97x net
Annual meeting vote results disclosed; routine director/auditor approvals
Q1 FY26 10-Q; portfolio activity steady, credit watchlist still elevated
Q1 FY26 10-Q; portfolio activity steady, credit watchlist still elevated
Definitive proxy: routine director slate and advisor agreement matters
Definitive proxy filed for 2026 annual meeting; governance housekeeping
FY25 10-K: NI $33.9M (-41%), EPS $0.39, equity -1.5%, dividends -16% YoY
FY25 10-K: NI $33.9M (-41%), EPS $0.39, equity -1.5%, dividends -16% YoY
Source: EODHD. Yield = trailing-12-month dividends ÷ price.
1049 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
| 2026-03-16 | CALDWELL PHYLLIS R Director | Buy | 2.50K @ $10.77 | $26.9K |
| 2026-03-16 | Gero Deborah Ann Director | Buy | 2.00K @ $10.78 | $21.6K |
| 2025-09-15 | CALDWELL PHYLLIS R Director | Buy | 2.00K @ $13.19 | $26.4K |
| 2025-09-15 | CALDWELL PHYLLIS R Director | Buy | 25.00 @ $13.19 | $329.75 |
| 2025-09-15 | CALDWELL PHYLLIS R Director | Buy | 975.00 @ $13.20 | $12.9K |
| 2025-06-30 | Gero Deborah Ann Director | Buy | 2.50K @ $13.70 | $34.3K |
| 2025-05-15 | Panossian Armen See Remarks | Buy | 8.00K @ $14.13 | $113K |
| 2025-05-07 | CALDWELL PHYLLIS R Director | Buy | 2.00K @ $13.33 | $26.6K |
| 2025-05-06 | Jacobson Craig A Director | Buy | 14.9K @ $13.41 | $200K |
| 2025-02-25 | CALDWELL PHYLLIS R Director | Buy | 2.50K @ $15.83 | $39.6K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.